Pw Medtech Group Ltd. (1358.HK) Trading Overview
- Last closing price: HKD 0.90
- 24‑hour change: –3.31 % (down to HKD 0.90 at 10:35 PM CET on Friday 23 Nov 2026)
- Shares outstanding: 1.4 billion
- Market capitalization: HKD 166.1 million
- Trading volume (last 24 h): HKD 138.3 k
- Monthly change: –1.69 % since the end of the previous month
- 200‑day simple moving average: HKD 1.10
- 52‑week high: HKD 1.52 (31 Oct 2025)
- 52‑week low: HKD 0.86 (13 Oct 2026)
Recent Corporate Development
Pw Medtech Group Ltd. received notice from its subsidiary, Sichuan Ruijian Medical. The subsidiary’s board has proposed voluntarily delisting its shares from the National Equities Exchange and Quotations (NEEQ). The decision will be finalized at an extraordinary general meeting scheduled for 6 November 2026. The announcement prompted a modest rise in Pw Medtech’s share price, reflecting market interest in the strategic shift of the subsidiary, which manufactures blood‑purification medical devices.
No additional information on the rationale for the delisting has been disclosed.
Related Stock Performance (Last 24 h)
| Symbol | Current Price | % Change | Market Cap | P/E Ratio |
|---|---|---|---|---|
| 1645.HK (Haina Intelligent Equipment) | HKD 2.58 | –2.08 % | HKD 190.7 mn | 70.33 |
| 1111.HK (Huashi) | HKD 0.23 | –4.55 % | HKD 186.5 mn | 2.19 |
| 9991.HK (Baozun) | HKD 8.6 | –10.9 % | HKD 199.2 mn | — |
| EURK (Eureka Acquisition) | USD 11.55 | 0 % | USD 25.1 mn | — |
| 3818.HK (China Dongxiang) | HKD 0.26 | –1.92 % | HKD 196.3 mn | — |
Notable Events – Baozun (9991.HK)
On 23 Oct 2026, Baozun filed a Form 4 with the SEC, reporting a change in beneficial ownership by its CEO, Qiu Wenbin. The CEO, through his Singapore‑based subsidiary JESFUND (SINGAPORE) PTE. LTD., acquired additional American Depositary Shares. The transactions on 21–22 Oct increased the CEO’s indirect holdings to over 1.5 million shares. No other material events were disclosed.
Company Profile – Pw Medtech Group Ltd.
Pw Medtech Group Ltd. is a China‑based developer, manufacturer, and marketer of medical devices. Its product portfolio focuses on infusion products and orthopedic implant products. The company operates within the broader medical technology sector and maintains a presence on the Hong Kong Stock Exchange under the ticker 1358.HK.